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Abstract:We report a case of disseminated infection with
Acanthamoeba in a patient with graft-versus-host disease after
hematopoietic stem cell transplant (HSCT) for acute lymphocytic
leukemia.The infection involved the brain, skin, and lungs and
occurred despite treatment with voriconazole for mold prophylaxis, and
did not respond to treatment with multiple other agents reported to
have activity against Acanthamoeba. To our knowledge, infection with
Acanthamoeba has been reported in 4 other patients after HSCTor bone






















































































Despite widespread dissemination in the environment,
Acanthamoeba are a rare cause of human diseases. Amebic
keratitis (AK), granulomatous amebic encephalitis (GAE)
with or without dissemination, and skin lesions are the
most commonly reported clinical patterns (1, 2). W|th the
exception of AK, infection with Acanthamoeba has been
reported primarily in immunosuppressed patients. Most
reports have been in patients with acquired immunode¢-
ciency syndrome (AIDS), and only 4 patients, all post mort-
em, with GAE with or without disseminated disease after
bone marrow or hematopoietic stem cell transplant (HSCT)
have been described (2^9).
While no standard treatment for infection with Acanth-
amoeba has been described, a variety of agents have activ-
ity in vitro, in animal models, or have shown success in case
reports (10^16). Recently, a case report suggested clinical
response to voriconazole and amphotericin B in a lung
transplant patient with skin lesions, and in vitro activity
of voriconazole against some species of Acanthamoeba
has been described (13, 15). We report the ¢rst case of
Acanthamoeba infection in a peripheral blood stem cell
transplant (PBSCT) recipient diagnosed ante-mortem.
In this patient, probable GAE with con¢rmed skin and
pulmonary lesions developed despite the long-term prophy-
lactic use of voriconazole to prevent invasive fungal infec-
tion in the setting of chronic graft-versus-host disease
(GVHD).
Case report
The patient was a 53 -year-old man with a history of acute
lymphocytic leukemia who received a matched unrelated
donor for PBSCT 930 days before presentation. The
patient’s post-transplant course was complicated by exten-
sive chronic GVHD of the skin, eyes, mouth, and liver. The
patient’s home regimen of immunosuppression included
tacrolimus 0.5 mg twice daily, mycophenolate mofetil
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1 g twice daily, and methylprednisolone 20 mg daily. As
antimicrobial prophylaxis, the patient was taking
voriconazole 200 mg twice daily, acyclovir 400 mg twice
daily, penicillin V 500 mg twice daily, and trimethoprim/
sulfamethoxazole (TMP/SMX) 1 double-strength tablet
twice a day on 2 days a week.
The patient was admitted to the hospital with sepsis and
had bacteremic Pseudomonas aeruginosa pneumonia
requiring mechanical ventilation. Because the patient
remained poorly responsive, computed tomography (CT)
of the head was performed and revealed an area of hyper-
density in the left periventricular area suggestive of
subacute hemorrhage. Magnetic resonance imaging
con¢rmed this impression, and because of hemorrhage, no
comment on enhancement could be made (F|g. 1).
The patient’s mental status improved and 3 days later he
was transferred out of the intensive care unit. He developed
fewer than10 papular and ulcerated skin lesions on his face,
leg, and arms (F|g. 2); biopsy was performed. Hematoxylin
and eosin staining revealed amebic trophozoites and cyst
forms (F|g. 3). Immunohistochemistry staining con¢rmed
infection with Acanthamoeba (not shown).
The patient was started on treatment with liposomal
amphotericin B (Ambisome) 5 mg/kg daily in combination
withTMP/SMX (5 mg/kg of the trimethoprim component)
every 8 h. The patient received 3 weeks of treatment
without signi¢cant change in the skin or central nervous
system (CNS) lesions, although no new skin lesions were
observed. Miltefosine 100 mg daily was obtained with
US Food and Drug Administration (FDA) approval for
emergency use, and TMP/SMX and liposomal ampho-
tericin were discontinued and voriconazole 300 mg twice
daily was restarted.
The patient developed worsening pulmonary status and
patchy in¢ltrates on CTof the chest and was treated with
ceftazadime 2 g every 8 h, and amikacin 500 mg inhaled
twice a day. Over the next 2 weeks, the patient’s condition
deteriorated, and he developed mental status changes and
increasing oxygen requirements.The patient died 5 weeks
after the diagnosis of Acanthamoebawas originally made.
Autopsy was performed, and examination of the brain
revealed hemorrhagic necrosis; the histology was consis-
tent with GAE, but no organisms were identi¢ed in or near
the hemorrhage (F|g. 4). In the lungs, areas of necrosis and
consolidation were not visible grossly, but all random lung
Fig. 1. Axial £air magnetic resonance imaging demonstrating
1.8 cm  1.9 cm area of hyperintensity in the left basal ganglia most con-
sistent with parenchymal hemorrhage.
Fig. 2. Pustular lesions on left leg.
Fig. 3. Skin biopsy demonstrating cysts (arrows) within a suppurative
tissue reaction (hematoxylin and eosin,  400).
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sections from both lungs contained Acanthamoeba cysts
and trophozoites (F|g. 5).
Discussion
Infection secondary to Acanthamoeba is rare and very
di⁄cult to diagnose, and we present to our knowledge the
¢rst case diagnosed ante-mortem in a PBSCT or bone
marrow transplant recipient. Diagnosis is generally made
by observing trophozoites or cysts on tissue specimens.
Particularly in patients with hematological malignancies,
thrombocytopenia or poor overall condition, the opportu-
nity to obtain abrain biopsymaybe limited. Moreover, even
if a biopsy is obtained, sampling area or failure to recognize
the pathogen may limit diagnostic yield (17 ). In our case,
diagnosis was only made possible by the presence of skin
lesions that could be easily biopsied with little risk to the
patient.
Acanthamoeba are free-living ameba widely distributed
in the environment.They have been isolated in soil and vir-
tually any water source (e.g., tap or bottled water, contact
lens solutions) (2).Thus, in most cases not involving contact
lens solution, no speci¢c exposure is identi¢ed. The most
common clinical disease caused by Acanthamoeba is AK,
which is related to contact lens use and generally occurs
in immunocompetent individuals (2). CNS involvement, in
contrast, usually occurs in immunosuppressed individu-
als, and typically presents as a subacute meningoencepha-
litis with ring enhancing or hemorrhagic lesions. Skin
lesions with or without CNS lesions have also been
described (2, 15). Lung involvement, as occurred in our
patient, has been described in patients with GAE (2, 3).
While GAE was not proven by biopsy or autopsy in our
case, a subacute CNS hemorrhage in an unusual location
in the context of heavy immunosuppression, and cutane-
ously disseminated Acanthamoeba is suggestive of GAE.
Although AIDS is the most commonly reported risk fac-
tor for non-ocularAcanthamoeba, other risk factors include
solid organ transplantation, connective tissue disease, dia-
betes, cirrhosis, renal failure, malignancies, and tuberculo-
sis (1, 2, 18^21). CNS or disseminated disease may occur in
immunocompetent patients, but is rare.Three other reports
describe 4 patients with disease caused byAcanthamoeba
after HSCT or bone marrow transplant (Table 1) (3, 4, 9).
Interestingly, 3 of the 5 patients (including this report) had
proven Acanthamoeba pneumonia at autopsy, and nodular
in¢ltrates were noted weeks before the development of
mental status changes. The range of time from ¢rst likely
clinical manifestation to death was 11^82 days. In all cases
except ours, diagnosis was made on post-mortem examina-
tion, so no comments regarding the e⁄cacy of treatment
can be made.
An instructive aspect of our case is the occurrence of
Acanthamoeba infection in a patient with GVHD treated
with long-term voriconazole as prophylaxis (200 mg twice
a day) against invasive fungal infection.The antifungal ac-
tivity of voriconazole is based on inhibition of synthesis of
ergosterol, which is also present in the plasmamembrane of
Acanthamoeba, providing a theoretical rationale for the
anti-amebic activity of voriconazole observed in vitro (13).
In one study, the in vitro activity of voriconazole was ob-
served in 3 species of Acanthamoeba representative of the
species most commonly found in clinical isolates (13). A
case report demonstrated obvious improvement in cutane-
ous lesions in a lung transplant patient with skin disease
treated with the combination of lipid amphotericin B and
voriconazole (15). Our case, however, suggests that
voriconazole may not always be e¡ective. This may be sec-
Fig. 4. Gross autopsy photo (brain) demonstrating a 1.9 cm hemorrhage
with hemosiderin rim in the left frontal posterior periventricular white
matter.
Fig. 5. Section of lung demonstrating numerous Acanthamoeba cysts
and trophozoites (magni¢cation  40). Arrows indicate trophozoites.
Arrowheads indicate cysts.
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ondary to poor absorption of the drug, inadequate dose, the
overall state of immunosuppression of the patient, or poor
activity against the particular species of Acanthamoeba in-
fecting our patient. Miltefosine (hexadecylphosphocholine)
is an anti-neoplastic agent that has been used to treat
visceral leishmaniasis, and has in vitro activity against
Acanthamoeba species, and clinical success has been
described in a single case report (13, 16). The drug is not
FDA-approved for use for any indication in the United
States, but may be obtained for emergency use through
the FDA. As Acanthamoeba cannot be grown in culture
in clinical microbiology labs, susceptibility testing is
generally not available.
Conclusion
We describe the ¢rst case, to our knowledge, of infection
with Acanthamoeba diagnosed ante-mortem in an HSCT
recipient. A high index of suspicion is necessary to make
this diagnosis. Disease developed despite long-term
prophylactic administration of voriconazole, and the
patient did not respond to combination therapy with
multiple agents reported to have activity against Acanth-
amoeba in vitro, in animal models, or in clinical case
reports.
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pulmonary lesions and GAE
Skin and lungs with
Acanthamoeba
Necrosis and hemorrhage
in brain; no organisms seen
First day of symptoms
day 930
Died day 965
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lymphocytic leukemia; CT, computed tomography; GAE, granulomatous amebic encephalitis.
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